Rutgers Cancer Institute of New Jersey Reporting Date: 03/31/2023 Data Table 2A – Active Funded Projects

Peer-Reviewed Training: Rutgers

Pl	Specific Funding Source	Project Number	Project Start Date	Project End Date	Project Title	Annual Project Direct Costs	Cancer- Relevant Annual Project DC	Program Code	Program Percent	Annual Program Direct Costs
Aleksunes L	NIEHS	2T32ES007148-36	9/1/1987	6/30/2027	TRAINING IN ENVIRONMENTAL TOXICOLOGY	\$601,263	\$601,263	Т	100	\$601,263
Aleksunes L Laskin D	NIEHS	5R25ES020721-12	8/9/2011	4/30/2026	SUMMER RESEARCH EXPERIENCE PROGRAMS (R25)	\$99,902	\$74,927	Т	50	\$37,463
								Т	50	\$37,463
Brewer G Soto M (Rutaers)	NIGMS Rutgers	5K12GM093854-11	8/1/2010	8/31/2023	BIOMEDICAL SCIENCE EDUCATION POSTDOCTORAL TRAINING PROGRAM	\$986,961	\$246,740	Т	100	\$246,740
Brewer G Soto M (Rutgers)	NIGMS Rutgers	3K12GM093854-11S1	9/1/2022	8/31/2023	BIOMEDICAL SCIENCE EDUCATION POSTDOCTORAL TRAINING PROGRAM (SUPPLEMENT)	\$908,410	\$227,103	Т	100	\$227,103
Chaudhary S	NCI	7R25CA247785-03	9/1/2020	11/30/2025	RUTGERS YOUTH ENJOY SCIENCE (RUYES) PROGRAM	\$328,247	\$328,247	Т	100	\$328,247
Dutta S	NSF	2018884	10/1/2020	9/30/2025	RCN-UBE: ENGAGING EDUCATORS IN DEVELOPING AND USING MOLECULAR CASE STUDIES AT THE INTERFACE OF BIOLOGY AND CHEMISTRY	\$100,000	\$25,000	Т	100	\$25,000
Graber J Shah N	NHLBI	7F31HL160196-02	8/1/2021	8/31/2023	BARRIERS AND PREDICTORS OF PHYSICAL FITNESS AMONG VOLUNTEER FIREFIGHTERS	\$39,013	\$39,013	Т	100	\$39,013
Heckman C Niu Z	NIMHD	7K99MD016435-02	4/15/2022	1/31/2024	DEVELOPING AND TESTING A MOBILE HEALTH INTERVENTION TO PROMOTE SUN PROTECTION BEHAVIORS AND SKIN EXAMINATION AMONG HISPANICS	\$115,885	\$115,885	Т	100	\$115,885
Hou P	NCI	7K22CA251491-02	12/1/2021	11/30/2024	TUMOR-TAMS CROSSTALK ENABLES BYPASS OF ONCOGENIC KRAS DEPENDENCY IN PANCREATIC CANCER	\$185,445	\$185,445	Т	50	\$92,723
								Т	50	\$92,723
Jeong M	NCI	7K01CA242591-04	9/1/2019	8/31/2024	THE IMPACT OF E-CIGARETTE MARKETING FEATURES ON YOUTHS' E- CIGARETTE PERCEPTIONS AND USE INTENTIONS	\$175,561	\$175,561	Т	100	\$175,561
Kohler R	NCI	1K22CA258675-01A1	8/2/2022	7/31/2025	ADDRESSING HPV VACCINATION DISPARITIES THROUGH TAILORED MESSAGING FOR HESITANT FAMILIES	\$203,610	\$203,610	Т	100	\$203,610
Radovick S	NCATS	7KL2TR003018-05	3/11/2019	2/29/2024	NEW JERSEY ALLIANCE FOR CLINICAL TRANSLATIONAL SCIENCE: INSTITUTIONAL CAREER DEVELOPMENT CORE	\$560,342	\$140,086	Т	100	\$140,086
Rameshwar P Fitzhugh V (Rutgers)	NHLBI Rutgers	7R25HL150544-03	7/1/2020	6/30/2025	MULTIDISCIPLINARY OPPORTUNITIES IN RESEARCH EDUCATION FOR STUDENTS IN HEALTH PROFESSIONS (MORESHP)	\$96,639	\$48,320	Т	100	\$48,320
Rasin M	NINDS	7R25NS105143-05	1/1/2018	12/31/2023	SUMMER UNDERGRADUATE RESEARCH PROGRAM (SURP) IN MOLECULAR AND DEVELOPMENTAL NEUROBIOLOGY	\$96,420	\$24,105	Т	100	\$24,105
Runnels L Haimovich B	NIGMS	5T32GM139804-02	2/1/2021	1/31/2026	IMSD AT RUTGERS - NEW BRUNSWICK	\$465,920	\$116,480	Т	50	\$58,240
								Т	50	\$58,240
Scotto K	NCATS	7TL1TR003019-05	3/11/2019	2/29/2024	NEW JERSEY ALLIANCE FOR CLINICAL TRANSLATIONAL SCIENCE: NRSA TRAINING	\$362,734	\$181,367	Т	100	\$181,367
Verzi M Nguyen M	NCI	5F31CA254086-03	9/1/2020	8/31/2023	FUNCTIONS OF KAT2A AND KAT2B IN INTESTINAL HOMEOSTASIS AND COLON CANCER	\$42,742	\$42,742	Т	100	\$42,742
Yarmush M Stock A	NIGMS	5T32GM135141-03	7/1/2020	6/30/2025	RUTGERS BIOTECHNOLOGY TRAINING PROGRAM	\$431,520	\$323,640	Т	100	\$323,640
Zeinomar N	NCI	1K22CA251493-01A1	8/1/2022	7/31/2025	LEVERAGING HIGH-RISK POPULATIONS FOR PRECISION PREVENTION: A NOVEL APPROACH FOR IMPROVING RISH PREDICTION FOR OUTCOMES AFTER A BREAST CANCER DIAGNOSIS	\$185,089	\$185,089	Т	100	\$185,089
Zong W Kang Y (Princeton)	NCI	5T32CA257957-02	4/1/2021	3/31/2026	POST-DOCTORAL TRAINING PROGRAM IN CANCER METABOLISM AND TUMOR-HOST INTERACTIONS	\$146,184	\$146,184	Т	100	\$146,184
					Peer-Reviewed Training Subtotals	\$6,131,887	\$3,430,807			\$3,430,807

Non-Peer-Reviewed Training: Rutgers

PI	Specific Funding Source	Project Number	Project Start Date	Project End Date	Project Title	Annual Project Direct Costs	Cancer- Relevant Annual Project DC		Program Percent	Annual Program Direct Costs
Bandera E Amin S	NJCCR	COCR22PDF007	7/1/2021	6/30/2023	NEOADJUVANT CHEMOTHERAPY AND TARGETED THERAPIES IN OVARIAN CANCER: RACIAL DISPARITIES IN USE AND SURVIVAL OUTCOMES	\$50,000	\$50,000	Т	100	\$50,000
Cao J Marshall G	NJCCR	COCR23PRF004	6/1/2022	5/31/2024	HEPATITIS B VIRUS INTEGRATIONS IN KMT2B DRIVE HEPATOCELLULAR CARCINOMA	\$96,300	\$96,300	Т	100	\$96,300

Part					1	COMBINING NONSENSE-MEDIATED MRNA DECAY BLOCKADE AND		ı	1		
Service Serv		NJCCR	COCR23PDF018	6/1/2022	5/31/2024	PERSONIZED VACCINE TO TARGET NEW FRAME-DERIVED TUMOR	\$155,999	\$155,999	Т	100	\$155,999
Barriary		NJCCR	COCR22PDF004	7/1/2021	9/30/2023	PATIENTS FOR THE DEVELOPMENT OF NOVEL T CELL RECEPTOR-	\$50,000	\$50,000	Т	100	\$50,000
Devine Residuary K		NJCCR	COCR23PDF028	7/1/2022	6/30/2024	IN BLADDER CANCER USING GENOMIC APPROACHES	\$192,271	\$192,271	Т	100	\$192,271
22ming T NUCK COM22PRE01 771/2021 6302023 CAUCKER CA		NJCCR	COCR22PDF003	7/1/2021	6/30/2023	MINDFULNESS-BASED MOBILE APPLICATION SERVICE IMPLEMENTATION FOR ADOLESCENTS AND YOUNG ADULTS WITH	\$50,000	\$50,000	Т	100	\$50,000
Searce S		NJCCR	COCR22PDF008	7/1/2021	6/30/2023		\$50,000	\$50,000	Т	100	\$50,000
No.		NJCCR	COCR22PRF011	7/1/2021	6/30/2023	ELUCIDATING THE ROLE OF LYN SRC KINASE IN DNA REPAIR	\$25,000	\$25,000	Т	100	\$25,000
Appelle NUCR		NJCCR	COCR22PRF006	7/1/2021	6/30/2023		\$25,000	\$25,000	Т	100	\$25,000
Mang W No.CR COCR25PR003 71/12021 6/30/2023 SUPPRESS TANDES UNPROTECTION AND SKINE EXAMINATION \$20,833 \$20,833 \$7 100 \$20,030		NJCCR	COCR22PDF009	7/1/2021	6/30/2023		\$50,000	\$50,000	Т	100	\$50,000
Nu Z NLCR COCR22PF007 7/1/2021 6/30/2023 PRACTICES AMONG HISPANICS \$20.83 \$20.83 \$20.83 \$1 100 \$50.00 \$50.00 \$50.00 \$10 \$50.00 \$50.00 \$50.00 \$10 \$50.00 \$50.00 \$50.00 \$10 \$50.00 \$50.00 \$10 \$50.00 \$50.00 \$10 \$50.00 \$50.00 \$10 \$50.00 \$10 \$50.00 \$10 \$50.00 \$10 \$50.00 \$10 \$50.00 \$10 \$50.00 \$10 \$10 \$50.00 \$10 \$10 \$10 \$10 \$10 \$10 \$10 \$10 \$10 \$		NJCCR	COCR23PDF004	7/1/2022	6/30/2024	SUPPRESS KRAS-DRIVEN LUNG TUMORIGENESIS	\$200,000	\$200,000	Т	100	\$200,000
Da Silva Da M NUCR COCK22PH-002 /17/2021 6/30/2023 ACT AS A ROYEL HELRAP-EDITIC PARSE IN INCELL LEUKAMA \$50,000 \$50,000 I 100 \$50,000 WAYANG X NUCCR COCK22PH-003 77/1/2022 6/30/2024 INTHE ITMOR MICROEM/IROMENT \$200,000 \$50,000 I 100 \$200,000 Libuti S Bagdasarov S NUCCR COCK22PH-003 77/1/2021 6/30/2023 USING HELRAP-ITMOR MICROEM/IROMENT LIGAND-DIRECTED A GALACTOSYL TRANSFERASE GENE THERAPY SUSING A COCK22PH-003 T/1/2022 6/30/2024 INTHE ITMOR MICROEM/IROMENT LIGAND-DIRECTED A GALACTOSYL TRANSFERASE GENE THERAPY SUSING A COCK22PH-003 T/1/2022 6/30/2024 INTHE ITMOR MICROEM/IROMENT LIGAND-DIRECTED A GALACTOSYL TRANSFERASE GENE THERAPY SUSING A COCK23PH-003 T/1/2022 6/30/2024 INTHE ITMOR MICROEM/IROMENT LIGAND-DIRECTED A GALACTOSYL TRANSFERASE GENE THERAPY SUSING A COCK23PH-003 T/1/2022 6/30/2024 INTHE ITMOR MICROEM/IROMENT LIGAND-DIRECTED A GALACTOSYL TRANSFERASE GENE THERAPY SUSING A COCK23PH-003 T/1/2022 6/30/2024 INTHE ITMOR MICROEM/IROMENT LIGAND-DIRECTED A GALACTOSYL TRANSFERASE GENE THERAPY SUSING A COCK23PH-003 T/1/2022 6/30/2024 INTHE ITMOR MICROEM/IROMENT LIGAND-DIRECTED A GALACTOSYL TRANSFERASE GENE THERAPY SUSING A COCK23PH-003 T/1/2022 6/30/2024 INTHE ITMOR MICROEM/IROMENT LIGAND-DIRECTED A GALACTOSYL TRANSFERASE GENE THERAPY SUSING A COCK23PH-003 T/1/2022 6/30/2024 INTHE ITMOR MICROEM/IROMENT LIGAND-DIRECTED A GALACTOSYL TRANSFERASE GENE THERAPY SUSING A COCK23PH-003 T/1/2022 6/30/2024 INTHE ITMOR MICROEM/IROMENT LIGAND-DIRECTED A GALACTOSYL TRANSFERASE GENE THERAPY SUSING A COCK23PH-003 T/1/2022 6/30/2024 INTHE ITMOR MICROEM/IROMENT LIGAND-DIRECTED A GALACTOSYL TRANSFERASE GENE THERAPY SUSING A COCK23PH-003 T/1/2022 6/30/2024 INTHE ITMOR MICROEM/IROMENT LIGAND-DIRECTED A GALACTOSYL TRANSFERASE GENE THERAPY SUSING A COCK23PH-003 T/1/2022 6/30/2024 INTHE ITMOR MICROEM/IROMENT LIGAND-DIRECTED A GALACTOSYL TRANSFERASE GENE THERAPY SUSING A COCK23PH-003 T/1/2022 6/30/2024 INTHE ITMOR MICROEM/IROMENT LIGAND-DIRECTED A GALACTOSYL TRANSFERASE GENE THERAPY SUSIN		NJCCR	COCR22PPR007	7/1/2021	6/30/2023		\$20,833	\$20,833	Т	100	\$20,833
Yang X NUCR OCR23PDF008 7/1/2022 6/30/2024 THE IMMINOSUPPRESISTE FOLIO F LEUKEMIA INHIBITORY FACTOR \$200,000 \$200,000 T 100 \$200,000		NJCCR	COCR22PDF002	7/1/2021	6/30/2023	ACLY AS A NOVEL THERAPEUTIC TARGET IN T-CELL LEUKEMIA	\$50,000	\$50,000	Т	100	\$50,000
In the Tumor Microentifold In the Tumor M		NJCCR	COCR22PDF010	7/1/2021	6/30/2023	MUTANT P53 SIGNALING IN BREAST CANCER	\$50,000	\$50,000	Т	100	\$50,000
LEDUTS Segregation Segre		NJCCR	COCR23PDF008	7/1/2022	6/30/2024		\$200,000	\$200,000	Т	100	\$200,000
Liu D Sabha Y NJCCR		NJCCR	COCR22PRF003	7/1/2021	6/30/2023	USING HYBRID AAV PHAGE VECTOR FOR ANTITUMOR IMMUNE	\$25,000	\$25,000	Т	50	\$12,500
Liu D									Т	50	\$12,500
Siebert J NJCCR		NJCCR	COCR23PRF010	7/1/2022	6/30/2024	IMMUNOSURVEILLANCE OF DRUG-RESISTANT LIVER CANCER TO	\$32,500	\$32,500	Т	100	\$32,500
NJCCR COCR23PDF002 7/1/2022 6/30/2024 ANTITUMOR T CELL ACTIVITY IN OVARIAN CANCER \$150,657 \$150,657 \$150,657 \$1 100 \$150,658 \$1		NJCCR	COCR23PRF20	6/1/2022	5/31/2024		\$25,000	\$25,000	Т	100	\$25,000
COCR23PDF006 T/1/2022 6/30/2024 IN AFRICAN AMERICAN AND HISPANIC BREAST CANCER SURVIVORS: \$75,870 \$75,870		NJCCR	COCR23PDF002	7/1/2022	6/30/2024	ANTITUMOR T CELL ACTIVITY IN OVARIAN CANCER	\$150,657	\$150,657	Т	100	\$150,657
Rrzyzanowska A NJCCR PRF036 7/1/2021 6/30/2024 UPON A FUNCTIONALLY UNIQUE T CELL SUBSET \$93,000 \$93,000 \$1 100 \$93,000 \$1 100 \$93,000 \$1 100 \$93,000 \$1 100 \$93,000 \$1 100 \$93,000 \$1 100 \$93,000 \$1 100 \$93,000 \$1 100 \$93,000 \$1 100 \$1		NJCCR	COCR23PDF006	7/1/2022	6/30/2024	IN AFRICAN AMERICAN AND HISPANIC BREAST CANCER SURVIVORS:	\$75,870	\$75,870	Т	100	\$75,870
Ibrahim M		NJCCR		7/1/2022	6/30/2024		\$93,000	\$93,000	Т	100	\$93,000
Galifi C NJCCR COCR23PRF013 6/1/2022 5/31/2024 OF BREAST CANCER EPITHELIAL CELLS 548,904 \$48,904 I 100 \$48,904 Wood T Galifi C NJCCR COCR23RBG003 6/1/2022 5/31/2024 NOVEL IGF1R FUNCTION IN BREAST TUMOR METASTATIS \$249,826 \$249,826 T 100 \$249,826 Zheng X Zhou T NJCCR COCR23PDF009 6/1/2022 5/31/2024 REGULATORY MECHANISMS OF ONCOGENIC CHROMATIN REMODELING \$81,546 T 100 \$81,546		NJCCR	COCR22PRF005	7/1/2021	6/30/2023		\$25,000	\$25,000	Т	100	\$25,000
Galifi C		NJCCR	COCR23PRF013	6/1/2022	5/31/2024		\$48,904	\$48,904	Т	100	\$48,904
Zhou T NJCCR COCK23PDF009 6/1/2022 5/31/2024 REMODELING \$81,546 \$81,546 I 100 \$81,546		NJCCR	COCR23RBG003	6/1/2022	5/31/2024	NOVEL IGF1R FUNCTION IN BREAST TUMOR METASTATIS	\$249,826	\$249,826	Т	100	\$249,826
Non-Peer-Reviewed Training Subtotals \$2,072,706 \$2,072,706 \$2,072,706		NJCCR	COCR23PDF009	6/1/2022	5/31/2024		\$81,546	\$81,546	Т	100	\$81,546
		\$2,072,706	\$2,072,706			\$2,072,706					